← Evidence map

ArticleNature communications2021

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Carla L Alves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. | OpenQuestion